Pacific Biosciences of California Inc Dossier
Qualitative Analysis
Business overview
Pacific Biosciences of California, Inc. (PacBio) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The company's products and technologies primarily consist of its Single-Molecule Real-Time (SMRT) HiFi long-read sequencing systems, which address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. PacBio operates in one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Dramatically improve the economics of HiFi sequencing and increase market penetration through the launch of SPRQ-Nx chemistry and multi-use SMRT cells.
Expected impact: Reduces sequencing costs to under $300 per genome at scale, improves gross margins, and increases sample throughput.
Accelerate clinical adoption of HiFi sequencing across key clinical applications including rare disease diagnostics, oncology, and carrier screening.
Expected impact: Aims to make clinical applications a substantial portion of the business within five years, leveraging the high accuracy of HiFi data to replace multiple existing tests.
Implement workforce reductions, facilities downsizing, and a refined development pipeline to lower operating expenses.
Expected impact: Reduces non-GAAP operating expenses to a projected $220 million to $225 million in 2026, down from $230 million in 2025.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to generate high-resolution long-read bulk RNA sequencing data from patient tumor samples to train and evaluate Blank Bio's RNA foundation models for precision oncology.
Terms: Announced alongside Blank Bio's $7.2 million seed financing round in May 2026.
Developed a robust joint extraction-to-library workflow enabling highly accurate HiFi long-read sequencing of formalin-fixed, paraffin-embedded (FFPE) tissue samples.
Terms: Collaborative development; specific financial terms were not disclosed.
Basecamp Research selected PacBio HiFi sequencing to power its Trillion Gene Atlas initiative to build a comprehensive biodiversity mapping database.
Terms: Specific financial terms were not disclosed.